Advances in chronic myeloid leukemia treatment, particularly regarding tyrosine kinase
inhibitors, mandate regular updating of concepts and management. A European …

In less than 10 years, the prognosis of chronic myeloid leukaemia has changed from that of
a fatal disease to a disorder amenable simply to lifelong oral medication and compatible …

This analysis explores the impact of early cytogenetic and molecular responses on the
outcomes of patients with chronic myeloid leukemia in chronic phase (CML-CP) in the phase …

Chronic myelogenous leukemia (CML) in children is relatively rare. Because of a lack of
robust clinical study evidence, management of CML in children is not standardized and often …

Immunological control may contribute to achievement of deep molecular response in chronic
myeloid leukemia (CML) patients on tyrosine kinase inhibitor (TKI) therapy and may promote …

We explored the impact of early molecular response (EMR; BCR-ABL≤ 10% on the
international scale [BCR-ABLIS] at 3 or 6 months) on outcomes in patients with newly …

We present long-term follow-up of a dasatinib phase 3 study of patients with imatinib-
resistant/-intolerant chronic myeloid leukemia (CML). In the CA180-034 study, 670 patients …

In chronic myeloid leukemia (CML) patients, a breakpoint cluster region–Abelson (BCR-
ABL1) value> 10% at 3 months of therapy is statistically associated with poorer outcome, yet …

Recent studies have demonstrated that some patients with chronic myeloid leukemia (CML)
can maintain remission after discontinuation of imatinib. A prerequisite is stable …

Early responses to tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML)-
chronic phase (CP) are associated with improved outcome. We analyzed the impact of such …